A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Time to progression (2 years after Last patient in)
Lucio Crino, MD
Principal Investigator
Bologna Italy
Italy: Ministry of Health
1839IL/0126
NCT00234468
January 2004
August 2007
Name | Location |
---|